Q1 2020 Entera Bio Ltd Earnings Call Transcript
Good morning, and welcome to Entera Bio's conference call to discuss the interim biomarker data from the Phase II clinical trial of EB613 and the financial and operating results from the first quarter of 2020. (Operator Instructions)
I would now like to turn the call over to Jon Lieber, the U.S.-based CFO of Entera. Please go ahead.
Thank you, and welcome to the call. Joining me on today's call are Adam Gridley, our CEO; Phillip Schwartz, our President of R&D; and Arthur Santora, our CMO. A press release announcing the interim data from the first 50% of the patients enrolled in the Phase II clinical trial of EB613 and Entera's financial and operating results for the quarter ended March 31, 2020, was issued earlier today. For those of you who have not yet seen it, it's available on the Investors section of our website, www.enterabio.com.
On our call this morning, we will share with you a business update and review our financial
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
